The Washington Post

Global enterprises must get involvedGlobal health: noncommunicable diseases

John Lechleiter

Chief Executive, Eli Lilly

We give money. We give medicines. We’re still going to do some of that, and that’s still important. But it’s not sufficient. We’re really, through our NCD program, applying the most precious commodity we have, which is our knowledge. We know a lot about the disease. We know a lot about treatment strategies. We probably don’t know as much as we could know about how to make diabetes diagnoses and treatment better in South Africa, or in Brazil, or in India or in Mexico, and that’s why we’re pursuing the NCD program.

Dr. John Lechleiter. (Marvin Joseph/WASHINGTON POST)

I think that global enterprises are going to be self-motivated to get engaged with this. I see a lot of activity within certain American companies.



Success! Check your inbox for details. You might also like:

Please enter a valid email address

See all newsletters

Show Comments

Sign up for email updates from the "Confronting the Caliphate" series.

You have signed up for the "Confronting the Caliphate" series.

Thank you for signing up
You'll receive e-mail when new stories are published in this series.
Most Read



Success! Check your inbox for details.

See all newsletters

To keep reading, please enter your email address.

You’ll also receive from The Washington Post:
  • A free 6-week digital subscription
  • Our daily newsletter in your inbox

Please enter a valid email address

I have read and agree to the Terms of Service and Privacy Policy.

Please indicate agreement.

Thank you.

Check your inbox. We’ve sent an email explaining how to set up an account and activate your free digital subscription.